EUVIMEDEUVIMED entdecken
Open Access

Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033

Johan M Kros, Elisabeth Rushing, Aimé L Uwimana, Aurelio Hernández-Laín, Alex Michotte, Maysa Al-Hussaini, Franck Bielle iD, Christian Mawrin, Gianluca Marucci, C Mircea S Tesileanu, Roger Stupp, Brigitta Baumert und 3 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Johan M Kros und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Laboratory for Tumor Immunopathology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Astrocytoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gliomas with IDH1/2 mutations without 1p19q codeletion have been identified as the distinct diagnostic entity of IDH mutant astrocytoma (IDHmut astrocytoma). Homozygous deletion of Cyclin-dependent kinase 4 inhibitor A/B (CDKN2A/B) has recently been incorporated in the grading of these tumors. The question of whether histologic parameters still contribute to prognostic information on top of the molecular classification, remains unanswered. Here we evaluated consensus histologic parameters for providing additional prognostic value in IDHmut astrocytomas.

Methods

An international panel of seven neuropathologists scored 13 well-defined histologic features in virtual microscopy images of 192 IDHmut astrocytomas from EORTC trial 22033-26033 (low-grade gliomas) and 263 from EORTC 26053 (CATNON) (1p19q non-codeleted anaplastic glioma). For 192 gliomas the CDKN2A/B status was known. Consensus (agreement ≥ 4/7 panelists) histologic features were tested together with homozygous deletion (HD) of CDKN2A/B for independent prognostic power.

Results

Among consensus histologic parameters, the mitotic count (cut-off of 2 mitoses per 10 high power fields standardized to a field diameter of 0.55 mm and an area of 0.24 mm2) significantly influences PFS (P = .0098) and marginally the OS (P = .07). Mitotic count also significantly affects the PFS of tumors with HD CDKN2A/B, but not the OS, possibly due to limited follow-up data.

Conclusion

The mitotic index (cut-off 2 per 10 40× HPF) is of prognostic significance in IDHmut astrocytomas without HD CDKN2A/B. Therefore, the mitotic index may direct the therapeutic approach for patients with IDHmut astrocytomas with native CDKN2A/B status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaAstrocytomaHumansPrognosisHomozygoteSequence DeletionMutationIsocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

CDKN2A/BIDH mutationastrocytomagliomagradingmolecular pathologyprognosisproliferation

Substanzen

Isocitrate DehydrogenaseCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Department of Pathology, Laboratory for Tumor Immunopathology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
  • Department of Neuropathology, University Hospital Zurich, University of Zurich, Switzerland.
  • European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Department of Pathology (Neuropathology), Hospital Universitario 12 de Octubre Research Institute, Madrid, Spain.
  • Medische Oncologie, Oncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel (AZ-VUB), Brussel, Belgium.
  • Department of Pathology and Laboratory Medicine, King Hussein Cancer Centre, Amman, Jordan.

ORCID-Profile: Franck Bielle, Pim J French

Förderung

  • Cancer Research UK
  • Medical Research Council

Zitieren

APA

Kros, J. M., Rushing, E., Uwimana, A. L., Hernández-Laín, A., Michotte, A., Al-Hussaini, M., Bielle, F., Mawrin, C., Marucci, G., Tesileanu, C. M. S., Stupp, R., Baumert, B., van den Bent, M., French, P. J., & Gorlia, T. (2023). Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac282

Vancouver

Kros JM, Rushing E, Uwimana AL, Hernández-Laín A, Michotte A, Al-Hussaini M, et al. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac282

BibTeX
@article{Kros2023,
  author = {Kros, Johan M and Rushing, Elisabeth and Uwimana, Aimé L and Hernández-Laín, Aurelio and Michotte, Alex and Al-Hussaini, Maysa and Bielle, Franck and Mawrin, Christian and Marucci, Gianluca and Tesileanu, C Mircea S and Stupp, Roger and Baumert, Brigitta and van den Bent, Martin and French, Pim J and Gorlia, Thierry},
  title = {Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac282}
}
Kostenlos starten →